Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Palbociclib-erythromycin pharmacokinetic interaction study
NL-OMON45801Phase 4Recruiting
- Sponsor
- Netherlands Cancer Institute
- Start
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of palbociclib and erythromycin in breast cancer (2 arms), sponsored by Netherlands Cancer Institute. Primary endpoints: Palbociclib AUC0-24h, Palbociclib Cmax and 1 more. Started Apr 2019; status: recruiting.
02
Drugs
palbocicliberythromycin
03
Conditions
breast cancer
Beyond the preview
Go deeper on NL-OMON45801.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON45801.